In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA) provide pathologist and medical oncologist perspectives about the detection and treatment of TRK fusion-positive lung cancers.
They discuss a number of techniques and strategies to identify this rare fusion in lung cancer patients, before going on to summarise the robust efficacy and safety data for both entrectinib and larotrectinib. Prof. Rolfo briefly covers second-generation therapies in clinical development and describes how liquid biopsy is emerging as a new technique not only to identify but also monitor patients. They conclude by stressing the importance of the collaboration and communication between pathologists and oncologists to test for and identify TRK fusion-positive lung cancer patients.
 
                        
                    COR2ED Medical Education: This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hospital,...
 
                        
                    COR2ED Medical Education: In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only,...
 
                        
                    In this podcast, Veerle Lamotte, an oncology nurse practitioner at Antwerp University Hospital and Paola Belardi, nurse chief at San Donato Hospital in Arezzo,...